Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (1)

Search Parameters:
Keywords = oxiapotophagy

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
20 pages, 3369 KiB  
Article
5,6-Epoxycholesterol Isomers Induce Oxiapoptophagy in Myeloma Cells
by Oumaima Jaouadi, Inès Limam, Mohamed Abdelkarim, Emna Berred, Ahlem Chahbi, Mélody Caillot, Brigitte Sola and Fatma Ben Aissa-Fennira
Cancers 2021, 13(15), 3747; https://doi.org/10.3390/cancers13153747 - 26 Jul 2021
Cited by 19 | Viewed by 2992
Abstract
Multiple myeloma (MM) is an incurable plasma cell malignancy with frequent patient relapse due to innate or acquired drug resistance. Cholesterol metabolism is reported to be altered in MM; therefore, we investigated the potential anti-myeloma activity of two cholesterol derivatives: the 5,6 α- [...] Read more.
Multiple myeloma (MM) is an incurable plasma cell malignancy with frequent patient relapse due to innate or acquired drug resistance. Cholesterol metabolism is reported to be altered in MM; therefore, we investigated the potential anti-myeloma activity of two cholesterol derivatives: the 5,6 α- and 5,6 β-epoxycholesterol (EC) isomers. To this end, viability assays were used, and isomers were shown to exhibit important anti-tumor activity in vitro in JJN3 and U266 human myeloma cell lines (HMCLs) and ex vivo in myeloma patients’ sorted CD138+ malignant cells. Moreover, we confirmed that 5,6 α-EC and 5,6 β-EC induced oxiapoptophagy through concomitant oxidative stress and caspase-3-mediated apoptosis and autophagy. Interestingly, in combination treatment a synergistic interaction was observed between 5,6 α-EC and 5,6 β-EC on myeloma cells. These data highlight a striking anti-tumor activity of 5,6 α-EC and 5,6 β-EC bioactive molecules against human myeloma cells, paving the way for their potential role in future therapeutic strategies in MM. Full article
(This article belongs to the Special Issue Advanced Therapies for Hematological Cancers)
Show Figures

Figure 1

Back to TopTop